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 CURRENTOPINION Advances in the understanding of headache
in idiopathic intracranial hypertension
Susan P. Mollana, Jan Hoffmannb, and Alexandra J. Sinclairc,d,e
Purpose of review
To review the most relevant developments in the understanding of headache in idiopathic intracranial
hypertension (IIH).
Recent findings
The phenotype of the typical IIH headache is diverging from the historical thinking of a raised intracranial
pressure headache, with the majority being classified as having migraine. A larger proportion of those with
IIH have a past medical history of migraine, compared with the general population, highlighting the
importance of re-examining those who have a change or escalation in their headache. The mechanisms
underlying headache in IIH are not understood. Additionally, factors which confer a poor headache
prognosis are not established. It is clear, however, that headache has a detrimental effect on all aspects
of the patient’s quality of life and is currently ranked highly as a research priority by IIH patients to better
understand the pathophysiology of headache in IIH and identification of potential headache specific
therapeutic agents.
Summary
Headache remains the predominate morbidity in the majority of those with IIH. Headache management is
an unmet need in IIH and future studies are required to investigate the probable complex mechanisms, as
well as effective management.
Keywords
headache, idiopathic intracranial hypertension, medication overuse headache, migraine, raised
intracranial pressure
INTRODUCTION
Idiopathic intracranial hypertension (IIH) is charac-
terised by an elevation of intracranial pressure (ICP)
with no identifiable cause [1
&&
]. There is a rising
incidence in this disease [2], and it appears that
the incidence is related to country specific preva-
lence of obesity [3]. It typically affects women of
working age [4] and headache is the predominant
morbidity in over 90% [4–7]. Headache is also
the key factor driving reduced quality of life in
IIH [8,9].
Previous characterisation of the typical pheno-
type of a raised ICP headache was of a nonspecific
headache that isworseonwaking. The featuresof IIH-
relatedheadachevarysubstantiallyand inthecontext
of the recent clinical studies that have characterised
them (Table 1), migraine is now the predominant
phenotype. Our understanding has changed and,
indeed, the international criteria have beenmodified
inwhichICP reduction isno longera requirement asa
diagnostic criterion of headache attributable to IIH
[10]. Caution does need to be applied before rapid
conclusions are drawn as to the relationship between
ICP and headache in the context of this rare disease
where less than200patientshavebeenreportedon, in
randomised controlled trials [11,12].
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REVIEW
HEADACHE AND THE PERSON WITH
INTRACRANIAL HYPERTENSION
Headache in IIH is known to have a detrimental
effect on quality of life [8,9] and chronic headaches
have a profound effect on people’s lives, showing
similarities with other pain conditions [13]. The
Idiopathic Intracranial Hypertension Treatment
Trial (IIHTT), a key trial, was a North American
multicentre, double-blind, randomised, placebo-
controlled study of 165 participants with investigat-
ing utility of acetazolamide in mild visual loss [11].
In this cohort, headache, particular when associated
with photophobia, was the major factor in detri-
mental general and visual quality of life [9,14
&&
].
In an observational study, headache frequency
and severity of depression symptoms were indepen-
dent predictors of disability in IIH with mean score
of 22.8 (15.2), compared with an average Italian
KEY POINTS
 Headache in IIH is heterogenesis; it occurs in any
location and the majority have headaches that have
characteristics of episodic and chronic migraine.
 Headache causes major morbidity in almost all patients
with IIH.
 There is likely to be a complicated relationship between
intracranial pressure, headache presence and disability
in both adults and children.
 There are no trials currently investigating the
management of headache in IIH.
Table 1. Summary of current studies that report headache characteristics in idiopathic intracranial hypertension
Reference
Study
characteristics
Number of participants
with IIH
Total number with/
without headache
Phenotype
(as per ICHD-3B)
Headache
frequency
Location
of pain
Friedman et al.
[14
&&
]
Randomised controlled
trial multicentre
included adults only at
38 sites in North
American
165 (161 female; 4
males)
144 reported headache
and 21 had no
headache at baseline
5 had no headache
throughout the study
52% migraine
22% tension-type
headache
16% probable migraine
4% probable tension-type
headache
7% unclassifiable
Mean frequency 12 days/
month at baseline
23% constant daily pain
and 38% reported to
use daily analgesic use
68% frontal
47% ocular
47% nuchal
39% posterior
36% global
30% unilateral
Hamedani et al.
[28
&
]
Retrospective cohort,
single centre included
children only in
Philadelphia, North
America
127 (64.6% were female
61 definite PTCS
10 probable PTCS
31 elevated opening
pressure no
papilloedema
25 normal opening
pressure and no
papilloedema
116 had headache
11 had no headache
– Of those with definite and
probable PTCS and
headache
Constant/daily 21/60
Episodic 26/60
Focal 19/60
Global 5/60
Head; neck;
shoulders 21/60
Raggi et al. [15] Observational, cross-
sectional single centre
included adults only in
Milan, Italy
51 (45 females; 6 males) 40 (78.4%) had
headache diagnosis
– Mean frequency 35.7 (SD
35.2) per 3 months
20 (39.2%) chronic
headache diagnosis
(migraine or tension
type on >15 days a
month for 3 months)
–
Sina et al. [20] Retrospective, single
centre included both
children and adults in
Tehran, Iran
68 (84% female; 16%
male)
– 63% migraine (of which
11% had migraine with
aura)
51% Chronic daily
headache
33% frontal
16% occipital
51% generalised
Yiangou et al.
[49]
Prospective, single centre
included adults only in
Birmingham, United
Kingdom
52 52 (100%) 80% migraine
35% attributed to raised
ICP
14% tension type
19% other/not classifiable
– –
Yri et al. [6] Prospective, single centre
included adults only at
the Danish Headache
Centre, Denmark
44 (98% female; 2%
male)
100% had headache 68% migraine
82% migraine attacks
<4h included
25% tension type
9% mixed migraine and
tension
5% unclassifiable
64% constant
86% daily
6% 2–4 days/week
2% <1 day/week
16% holocranial
52 frontal
34% temporal
23 parietal
34% occipital
50% frontal or fronto-
temporal
predominantly
34% neck
64% retrobular
66% bilateral
30% strictly unilateral
5% varying
ICP, Intracranial pressure; IIH, intracranial hypertension.
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general population of 12.9. This indicated that con-
sideration should be given to reducing headache
and treating depression in IIH [15]. In the United
Kingdom, the James Lind Alliance priority setting
partnership investigated over 500 IIH patients and
clinician preferences, understanding of headache
mechanisms and treatment was ranked in two
domains of the top 10 research priorities for IIH.
This reflects the unmet need of the disability of
headache in everyday life of our patients [16
&
].
PHENOTYPING INTRACRANIAL
HYPERTENSION-RELATED HEADACHE
Historically, a raised ICP headache is positional, with
nocturnal awakening, worse on waking and aggra-
vated by Valsalvamanoeuvre. Studies now have clas-
sified those with headache and IIH would meet the
InternationalHeadacheSociety criteria [10] ashaving
either episodic migraine, chronic migraine or
tension-type headache (Table 1). According to the
IIHTT, the quality of the pain was pressure-like in
47% and throbbing in 42% [14
&&
], which is similar to
migraine [17]. Photophobia, phonophobia, nausea,
vomiting and worsening on physical activity were
reported and none of these migraine features sepa-
rated IIHheadache frommigraine [14
&&
].Other symp-
toms included constant visual loss; transient visual
obscurations, diplopia and dizziness; these could
help distinguish primary migraine from migraine
in IIH;however, the authors cautioned that 14%with
headache and papilloedema had none of these asso-
ciated symptoms [14
&&
] (Table 2).
In children with pseudotumour cerebri (PSTC),
Lee et al. [18
&
] studied the difference in children’s
drawings of their headaches. A total of 21 children
with PSTC and 518 children with migraine showed
that drawings had similar features except one-third
(28.6%) with PSTC depicted diplopia which was
highly significant (P¼0.00001). Diplopic images
Table 2. Table comparing and contrasting clinical features between headaches in IIH and typical migraine
Headache in IIH Migraine
Yri et al. [6]
Clinical features IIHTT [9,14&&] IIH Controls
Kelman [17]
n¼1283
(84.3% female; mean
age 37.7 (SD 12 years)
Body mass index 40.0 (8.5) AZA arm
39.9 (8.1) placebo
34.6 30.8 –
ICP—lumbar puncture
opening pressure (cm CSF)
34.0 (SD 9.1) AZA arm
34.2 (SD 7.1) placebo
39.6 18.2 –
Photophobia 70% 66% – 84–95%
Phonophobia 52% 73% – 77–93%
Nausea 47% 75% – 90%
Vomiting 15% – – 19.8%
Dizzy symptoms 53% – – 36.1%
Neck pain 42% 34% – –
Shoulder pain – – – –
Back pain 53% – – –
Radicular pain 19% – – –
Worsening on valsalva – 70% 35% –
Worsening on bending – 52% 44% –
Aggravated by physical activity 50% 64% 74% 90% (13.5% occasionally;
32.2% frequently,
44.3% very frequently)
Pulsatile tinnitus 52% (bilateral in
two-thirds of these)
64% 26% –
Daily nonpulsatile tinnitus 23% – – –
Transient visual obscurations 68% 64% 35% –
Patient reported diplopia 18% 45% 24% –
Esotropia or 6th cranial nerve palsy 3% – – –
Papilloedema Yes Yes No No
AZA, Acetazolamide group; CSF, cerebrospinal fluid; ICP, intracranial pressure; IIH, intracranial hypertension.
Neuro-ophthalmology
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may serve as a useful ‘red flag’ for those who inves-
tigate children for raised ICP.
PRIOR HISTORY AND FAMILY HISTORY
OF HEADACHE
Prior history of headache in the IIHTT was found in
41% [14
&&
], which is similar to Yri et al. [6] who
found in 45% of their IIH cohort with 25% having
prior migraine and 34% having prior tension-type
headaches. This is nearly double that of the US
female population with 18% having history of
migraine [19]. Positive family history was high, with
one study reporting up to 68%of thosewith IIH [20].
These factors may be implicated in the pathophysi-
ology of headache in IIH. What is of importance is
the re-examination for papilloedema in those who
have a change or escalation in their headache [21].
HEADACHE OUTCOMES IN INTRACRANIAL
HYPERTENSION STUDIES
Overall, there are few studies investigating head-
ache; they report different headache outcomes
and have a small number of patients (Table 1),
and the results of which are not surprisingly con-
flicting in this rare disease.
HEADACHE SEVERITY AND FREQUENCY
Headache severity in IIH appears to be moderate to
severe. In the Birmingham prospective study inves-
tigating womenwith IIHwho followed a low-calorie
diet for 3 months, severity, as recorded using the
visual analogue pain score, was 4.2 (2.8) and
reduced to 1.9 (2.8), P¼0.015, at study end with
significantly reduced ICP compared with pressure
measured in the 3 months before the diet [22].
Others have reported higher severity of 5.6 (2.5)
[15], and the IIHTT baseline headache severity was
6.3 (1.9) on a 0–10 scale, with 5.4% reporting 10/
10 [9]. Differences could exist because of duration of
IIH and medication overuse headache.
Headache frequency in IIH is typically episodic in
new onset disease and chronic inmore longstanding
disease (Table 1). Both severity and frequency have
not appeared to correlate with lumbar puncture
openingpressure in the IIHTT [14
&&
], and theportions
between episodic and chronic could reflect time to
enrolment from diagnosis, or onset of raised ICP, or
existence of other coexisting headache phenotypes.
HEADACHE DISABILITY SCORE
The Headache Impact Test (HIT)-6 [23], which is a
validated for use across headache disorders, is
commonly used [24]. Most agree at baseline the
HIT-6 measures substantial to severe impact on
IIH patients. Headache disability is multifactorial,
and comorbid conditions can influence disability
for example thosewith a high risk of sleep apnoea, as
determined by the Berlin questionnaire, had a
higher HIT-6 score in the IIHTT (P¼0.04) [14&&].
In the Birmingham weight loss study [22], base-
line HIT-6 was 57.5 (9.0) which significantly
improved after weight loss to 46.9 (10.1)
(P¼0.004). The IIHTTHIT-6mean baseline was simi-
lar to59.7 (9.0) reducingbotharmsbyover 9points,
which did not reach significance [14
&&
]. In an open-
label extensionof the IIHTT [25], 96participantswere
sorted into remaining on acetazolamide (n¼34),
switch placebo to acetazolamide (n¼35), switch acet-
azolamide to no treatment (n¼16) and switch pla-
cebo to no treatment (n¼11). At month 12, those
switched placebo to acetazolamide had significant
improvement HIT-6 with 3.70 point reduction
(P¼0.01). This is an interesting fact; however, cau-
tion must be used in interpreting this as headache
outcomes are prone toplacebo effects and total blind-
ing to treatment allocation is hampered by knowl-
edge of trial arm allocation and through the
experience of drug-related side-effects (such as use
of acetazolamide andexperiencingparaesthesia) [26].
HEADACHE RELATIONSHIP TO
INTRACRANIAL PRESSURE
The relationship between headache and degree of
ICP elevation is not fully delineated and is likely to
be complicated. Younger age (P¼0.03) of onset and
high lumbar puncture opening pressure (P¼0.03)
have both been associated with better odds of being
without headache or with only infrequent headache
(<1 day/month) headache after 12 months [6].
Amongst IIHTT cohort, therewasno relationship
found between the mean lumbar puncture opening
pressure, 343.5 (86.9) and the presence or absence
of headache at baseline [14
&&
]. This potentially sug-
gests an individual threshold of tolerance of differing
degrees of ICP and that once elevated other factors
may contribute to chronicity. Analogies maybe
drawn to posttraumatic headache in which suscepti-
bility is influenced by previous migraine history,
childhood migraine and family history of migraine,
potentially suggesting an underlying genetic predis-
position to headache and not necessarily a clear
correlation between degree of trauma. Other inves-
tigators have supported theories that headache in IIH
is attributed to more complex mechanisms than ICP
elevation alone [27].
The IIHTT highlighted that there was no statis-
tical relationship found between headache severity
Advances in the understanding of headache Mollan et al.
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(0–10 scale) and ICP, at both baseline and trial end.
Only half agreed to have a lumbar puncture at
6 months (65 had headache and 20 without) and
there was no correlation between HIT-6 and lumbar
puncture opening pressure (r¼0.12; P¼0.29), but
the number of headache days weakly correlated
(r¼0.12, P¼0.04). Lumbar puncture opening pres-
sure changed by 112.3mm cerebrospinal fluid (CSF)
in the acetazolamide group and 52.4mm CSF in the
placebo group (P¼0.002) and both arms reported
headaches (69% acetazolamide and weight loss arm;
68% placebo and weight loss arm) [14
&&
].
In the Birmingham weight loss study, lumbar
punctureopeningpressurewas 38.0 (5.0) at the start
of the diet and 30.0 (4.9) (P<0.001). HIT-6 signifi-
cantlyimprovedwiththisreductioninICP(P¼0.004)
and there were significant improvements, by greater
than 50%, in headache severity (visual analogue pain
score (0–10) from4.2 (2.8) to1.9 (2.8), (P¼0.015),
headache frequency from4.4 (2.9) to2.1 (2.8)days
a week (P¼0.011), and weekly use of analgesics from
2.2 (2.5) to 0.2 (0.4) days a week (P¼0.007).
Patients’ symptoms(headache, tinnitus,obscurations
and diplopia) showed significant improvement after
the low energy diet (P<0.001, P¼0.004, P¼0.025
and P¼0.008, respectively) One explanation of the
difference between this study [22] and IIHTT [14
&&
], in
which the magnitude CSF pressure reduction was
similar, may be that the Birmingham study assessed
the intervention at 3 months, compared with
6 months in the IIHTT.
In children with IIH, Hamedani et al. [28
&
] ret-
rospectively reported headache characteristics. They
detailed headache pattern from clinical records,
severity (subjectively determined) and location
along with associated symptoms of visual change
and nausea. There was no difference between the
groups in terms of pain severity, and presence of
nausea, despite there being distinct differences in
median lumbar puncture opening pressure between
definite PTCS (39 cm CSF), probable PTCS (24 cm
CSF), elevated opening pressure (35 cm CSF) and
normal opening pressure group (23 cm CSF)
(P<0.001). It may be that once ICP is over a ‘patient
specific threshold’ headache will occur, but the
absolute degree of ICP elevation may not be the
primary underlying mechanism.
MANAGEMENT OF HEADACHE IN
INTRACRANIAL HYPERTENSION
The 2015 Cochrane review concluded that there is a
lack of evidence to guide pharmacological treatment
in IIH [29]. There are few published randomised
clinical trials [11,12] and a small number of ongoing
trials [30,31]. None of these have focused on
management of headache. Managing headache in
IIH is an essential aspect of patient care and recent
consensus guidelines have provided a practical
approach to managing them [1
&&
].
MANAGEMENT OF MIGRAINE IN
INTRACRANIAL HYPERTENSION
As migraine is the predominant phenotype
(Table 1), the use of migraine therapies has been
recommended [1
&&
]. Migraine attacks may benefit
from triptan acute therapy used in combination
with either a nonsteroidal anti-inflammatory or
paracetamol and an antiemetic with pro-kinetic
properties [32
&
]. Their use should be limited to in
the region of 2 days/week or a maximum of 10 days/
month [32
&
]. Where medication overuse coexists,
this should be addressed, and if chronic migraine is
present, preventive strategies have been recom-
mended [1
&&
,33]. Caution should be observed before
selecting drugs that could increase weight such as b-
blockers, tricyclic antidepressants, sodium val-
proate, pizotifen and flunarizine. Care should be
taken in those medications that exacerbate depres-
sion which is a frequent co-morbidity in IIH, such as
b-blockers, topiramate and flunarizine [1
&&
].
A meta-analysis demonstrated that topiramate
was effective in reducing headache frequency and
was reasonably well tolerated in adult patients with
episodic migraine [34
&
]. It may have additional
benefits of suppressing appetite and have an effect
on reducing ICP through carbonic anhydrase inhi-
bition. In-vivo studies demonstrated that both sub-
cutaneous and oral administration of topiramate
significantly lowered ICP in rodents, whereas other
drugs tested, including acetazolamide, furosemide,
amiloride and octreotide, did not significantly
reduce ICP [35]. Topiramate utility in IIH reported
in an open-label study which randomly assigned 40
patients with IIH to acetazolamide or topiramate
and demonstrated treatment equivalence with all
experiencing improvement in visual fields [36].
Otherpreventive therapies, someofwhicharenot
licenced for migraine, could include candesartan
because of its lack of weight gain and depressive
side-effects [37]orpotentiallynon-invasiveneuromo-
dulation [38]. Botulinum toxin A, which is a licenced
therapyformigraine,couldalsobeusefulinthosewith
coexisting chronic migraine [39
&
]. Other strategies,
such as mindfulness, may suit some patients [40
&
].
MANAGEMENT OF MEDICATION OVERUSE
HEADACHE
One-third of IIHTT participants overused medica-
tion at baseline, on the basis of the last 30-day
Neuro-ophthalmology
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history, and had a significantly higher mean HIT-6
score (63.16.9) than in those without (58.19.4;
P¼0.0007) [14&&]. Other studies foundmanagement
of medication overuse headache (MOH) a more
common issue for IIH patients long term, reflecting
the study type [6]. Successfully removing excessive
analgesic use significantly improves headaches in
other headache disorders. What is yet what is yet to
be determined is the effects it has on the course of
IIH-related headache [41]. It seems prudent that
all IIH patients with headaches are warned about
avoiding excessive analgesic use and where MOH
exists standard advice of removal given [41,42].
THERAPEUTIC LUMBAR PUNCTURE
Professional bodies in the United Kingdom [1
&&
] and
Europe [43] do not advocate therapeutic lumbar
puncture as a treatment strategy for IIH. Although
lumbar puncture induces a transient reduction of
ICP, the effect is typically short lived with pressure
rising rapidly after the procedure [44]. There is
growing awareness regarding the morbidity of the
procedure [45,46]. IIH patients frequently report a
negative and emotional experience when they
undergo a lumbar puncture [47,48] and themajority
of active IIH patients (papilloedema and lumbar
puncture opening pressure >25 cm CSF) will face
an exacerbation of headache in the week following
lumbar puncture [49]. The long-term therapeutic
effects of lumbar puncture are not well known.
NEUROSURGICAL TREATMENT OF
HEADACHE
CSF shunting to exclusively treat headache in IIH
has limited evidence. About 68% will continue to
have headaches at 6 months and 79% by 2 years
following CSF diversion. A third have been reported
to develop iatrogenic low pressure headaches,
although this figure may be lower depending on
shunt and valve types [50]. There is uncertainty that
failure to optimise ICP may render the migraine
headaches difficult to treat, and if headache was
indicated for CSF shunting, then a period of ICP
monitoring preoperatively may be useful to deter-
mine the success of the proposed procedure [1
&&
].
INTERVENTIONAL VASCULAR STENTING
FOR HEADACHE
The literature detailing dural venous stenting typi-
cally does not clearly separate the cohorts of IIH into
those with acute visual loss and those with head-
aches. Many case series are small, nonrandomised,
do not detail morphological stenosis type and some
do not record the pressure gradient. There are
selection bias, differing treatment protocols, poor
characterisation of headache phenotype and a lack
of long-term follow-up [51]. Additionally, objective
validated headache outcome measures are infre-
quently utilised. Well characterised studies would
be welcomed in this area.
MANAGEMENT OF HEADACHES IN THE
SHUNTED PATIENT
Shunted patients may have significant headache
morbidity and understanding the underlying causes
may guide management. It has been recommended
that shunt revision should not routinely be under-
taken unless there is an assessment of vision for
papilloedema and there is a risk of visual deteriora-
tion [52]. There is little indication to perform shunt
series, as they do not determine shunt failure or
overdrainage or change management decisions
[53]. As with chronic headaches, removal of MOH
[53,54] and migraine treatments should be consid-
ered; additionally, ICP monitoring may be informa-
tive to direct treatment choices [1
&&
].
CONCLUSION
Migraine phenotype and prior history of headache
before a diagnosis of IIH needs to be recognised by
clinicians to avoid misdiagnosis. There is an unmet
need to treat headaches in IIH. Future studies should
consider core outcome measures for headache, as
used inmigraine trials, which would optimise meta-
analysis. Migraine abortive and preventive therapies
can be used, but currently there is no high-class
evidence to help guide treatment decisions.
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